5-APB 5-(2-aminopropyl)benzofuran - Expert Committee on Drug Dependence Information Repository

Alternative names

5-APB

Current Scheduling Status

N/A

Year(s) and type of review / ECDD meetings

Added to surveillance list by 2nd WG meeting (2017)

Drug Class

stimulant

Recommendation (from TRS)

Information has been brought to WHO’s attention that 5-APB is being misused in a number of Member States. 5-APB is clandestinely manufactured and has been identified in seized products. 5-APB produces amphetamine-like effects that include euphoria, increased blood pressure and temperature, decreased appetite, increased wakefulness and physical activity, along with rapid and/or irregular heartbeat. 5F-APB has been associated with fatal intoxications. To date, 5-APB has not been pre- or critically reviewed by the ECDD. Added to surveillance in 2017. Considered at the 9^th WG meeting (2021), where the committee determined that there was insufficient new information to justify a critical review.